aptaTargets announces positive preliminary data from the ApTOLL Phase 2a clinical trial for stroke

24 October, 2022

aptaTargets today announces that the preliminary results from the Phase 2a APRIL clinical trial for ApTOLL show that it is a safe and well-tolerated neuroprotective drug capable of reducing brain damage and improving the functional outcomes of patients who have suffered acute ischemic stroke.

The Phase 1b/2a APRIL clinical trial has been designed as a multicentre, randomised, double-blind and placebo-controlled study in which 151 patients have participated from 16 leading hospitals* in research and care for neurovascular diseases in Spain, Germany and France. The patients are men and women between the ages of 18 and 90 who have been administered ApTOLL intravenously combined with mechanical thrombectomy.

“We are pleased with the highly promising clinical results with patients. Although we have to wait for the final results of the study, we can expect that ApTOLL could become an important new therapeutic option for the treatment of acute ischemic stroke” explains Dr Marc Ribó, Chief Medical Officer of aptaTargets and interventional neurologist at the Vall d’Hebron University Hospital in Barcelona.

aptaTargets aims to present the final results from the trial during the International Stroke Conference which will be held in Dallas (US) in February 2023. “ApTOLL is the result of years of R&D based on innovative aptamer technology, talent and the effort of our team and the advice of renowned experts in the neurovascular field” notes David Segarra, CEO and Co-Founder of aptaTargets. “We are very satisfied with the preliminary data and excited that ApTOLL can improve these patients’ survival and quality of life” adds Segarra.

Acute ischemic stroke represents 85% of strokes and remains a great unmet medical need as it leads to devastating sequelae.

This news comes at the same time as the celebration of BIO Europe, from 24 to 26 October in Leipzig (Germany), where aptaTargets plans to have partnering meetings with investors and the pharmaceutical industry interested in licensing innovative molecules.

* Vall d’Hebron University Hospital, La Princesa University Hospital, Germans Trias i Pujol University Hospital, A Coruña University Hospital Complex, Bellvitge University Hospital, Ramón y Cajal University Hospital, Virgen del Rocío University Hospital, La Fe University Hospital, Doctor Josep Trueta University Hospital, University Clinical Hospital of Valladolid, 12 de Octubre University Hospital, Toulouse University Hospital, University Hospital of Lille, Hôpital Fondation Adolphe de Rothschild, University Hospital of Asturias, Essen University Hospital.